Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & F ...

NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...

Accessibility StatementSkip Navigation On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may cho ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Company: Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic Inducible Urticaria (“CIndU”), and Asthma. Class Period: November 30, 2023 - July 3, 2025 The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) because t ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...

NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

公司法律诉讼 - 律师事务所Faruqi & Faruqi正在调查针对Jasper Therapeutics Inc的潜在索赔 并提醒投资者关于2025年11月18日的首席原告申请截止日期 [3] - 诉讼指控公司及其高管违反联邦证券法 发布虚假和/或误导性陈述 未能披露其缺乏必要的控制与程序来确保第三方制造商完全符合cGMP规范 [5] - 上述指控导致公司业务和/或财务前景以及briquilimab的临床和/或商业前景被夸大 被告的公开陈述在所有相关时间均存在重大虚假和误导性 [5] 公司运营与产品问题 - 公司依赖于第三方制造商 但缺乏确保其生产完全符合cGMP规范且适用于临床试验的控制与程序 [5] - 2025年7月7日 公司报告BEACON研究更新数据 指出240mg Q8W和240mg后180mg Q8W剂量组的结果因一个特定药物产品批次的问题而受到干扰 该批次涉及13名患者中的10名 [6] - 有问题的药物批次也被用于ETESIAN研究 公司因此停止该研究并暂停哮喘领域的开发 同时停止SCID的开发 [6] 公司财务与股价影响 - 公司此前表示拥有强劲的资产负债表 现金可支撑运营至2025年第三季度 但宣布将实施一系列成本削减措施 包括潜在重组 以延长现金跑道并减少开支 [6] - 受此消息影响 Jasper股价于2025年7月7日下跌每股373美元 跌幅达551% 收盘报每股304美元 [6] - 前述问题增加了实施破坏性成本削减措施的可能性 [5]

公司法律诉讼 - 律师事务所Faruqi & Faruqi正在调查针对Jasper Therapeutics Inc (NASDAQ: JSPR)的潜在索赔 并提醒投资者关于2025年11月18日的首席原告申请截止日期 [1] - 诉讼指控公司及其高管违反联邦证券法 包括做出虚假和/或误导性陈述以及未能披露相关信息 [3] - 指控的具体内容包括公司缺乏必要的控制程序来确保第三方制造商完全遵守cGMP法规 这增加了混淆正在进行的研究结果的风险 [3] 公司产品与临床开发问题 - 2025年7月7日 公司报告BEACON研究的最新数据 指出240mg Q8W和240mg followed by 180mg Q8W剂量组的结果似乎受到一个特定药物产品批次问题的影响 该批次涉及的13名患者中有10名受到影响 [4] - 受影响的药物批次也被用于ETESIAN研究 因此公司决定停止该研究并暂停在哮喘领域的开发 同时也将停止在SCID（严重联合免疫缺陷病）领域的开发 [4] - 上述问题对公司产品briquilimab的监管和商业前景造成了负面影响 [3][4] 公司财务状况与股价表现 - 尽管公司此前表示拥有强劲的资产负债表 现金储备可支撑至2025年第三季度 但现已决定实施一系列成本削减措施 包括潜在的重组 以延长现金跑道并减少开支 [4] - 受此消息影响 Jasper股价在2025年7月7日下跌每股3.73美元 跌幅达55.1% 收盘报每股3.04美元 [4] - 公司的业务和/或财务前景以及briquilimab的临床和/或商业前景被指控为被夸大 [3]